Diversity analysis of 14 156 molecules tested by the National Cancer Institute for anti-HIV activity using the quantitative structure-activity relational expert system MCASE

Journal of Medicinal Chemistry

Volumn 42, Issue 6, 1999, Pages 992-998

  Klopman, Gilles ^a   Tu, Meihua ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANALYTIC METHOD; ANTIVIRAL ACTIVITY; ARTICLE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS; HYDROGEN BOND; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANTI-HIV AGENTS; DATABASES, FACTUAL; NATIONAL INSTITUTES OF HEALTH (U.S.); STRUCTURE-ACTIVITY RELATIONSHIP; UNITED STATES;

EID: 0033602543     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980451i     Document Type: Article

References (36)

1. Wilkerson, W. W.; Dax, S.; Cheatham, W. W. Nonsymmetrically substituted cyclic urea HIV protease inhibitors. J. Med. Chem. 1997, 40, 4079-4088.
2. Wei, D. T.; Meadows, J. C.; Kellogg, G. E. Effects of entropy of QSAR equations for HIV-1 protease: 1. Using hydropathic binding descriptors: 2. Unrestrained complex structure optimizations. Med. Chem. Res. 1997, 7, 259-270.
3. Thaisrivongs, S.; Romero, D. L.; Tommasi, R. A.; Janakiraman, M. N.; Strohbach, J. W.; Turner, S. R.; Biles, C.; Morge, R. R.; Johnson, P. D.; Aristoff, P. A.; Tomich, P. K.; Lynn, J. C.; Horng, M. M.; Chong, K. T.; Hinshaw, R. R.; Howe, W. J.; Finzel, B. C.; Watenpaugh, K. D. Structure-based design of HIV protease inhibitors: 5,6-Dihydro-4-hydroxy-2-pyrones as effective, non-peptidic inhibitors. J. Med. Chem. 1996, 39, 4630-4642.
4. Quere, L.; Wenger, T.; Schramm, H. J. Triterpenes as potential dimerization inhibitors of HIV-1 protease. Biochem. Biophys. Res. Commun. 1996, 227, 484-488.
5. Mazumder, A.; Wang, S.; Neamati, N.; Nicklaus, M.; Sunder, S.; Chen, J.; Milne, G. W. A.; Rice, W. G.; Burke, T. R.; Pommier, Y. Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease. J. Med. Chem. 1996, 39, 2472-2481.
6. Wang, S.; Milne, G. W. A.; Yan, X.; Posey, I. J.; Nicklaus, M. C.; Graham, L.; Rice, W. G. Discovery of novel, non-peptide HIV-1 protease inhibitirs by pharmacophore searching. J. Med. Chem. 1996, 39, 2047-2054.
7. Doweyko, A. M. Three-dimensional pharmacophores from binding data. J. Med. Chem. 1994, 37, 1769-1778.
8. Waller, C. L.; Oprea, T. I.; Giolitti, A.; Marshall, G. R. Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally determined alignment rules. J. Med. Chem. 1993, 36, 4152-4160.
9. Oprea, T. I.; Waller, C. L.; Marshall, G. R. Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors: 2. Predictive power using limited exploration of alternate binding modes. J. Med. Chem. 1994, 37, 2206-2215.
10. Tronchet, J. M. J.; Grigorov, M.; Dolatshahi, N.; Moriaud, F.; Weber, J. A QSAR study confirming the heterogeneity of the HEPT derivative series regarding their interaction with HIV reverse transcriptase. Eur. J. Med. Chem. 1997, 32, 279-299.
11. Mager, P. P.; De Clercq, E.; Takashima, H.;Ubasawa, M.; Sekiya, K.; Baba, M.; Walther, H. Molecular simulation of 5,6-substituted 1-((2-hydroxyethoxy)methyl)uracils with anti-HIV-1 activity. Eur. J. Med. Chem. 1996, 31, 701-712.
12. Hannongbua, S.; Lawtrakul, L.; Sotriffer, C. A.; Rode, B. M. Comparative molecular field analysis of HIV-1 reverse transcriptase inhibitors in the class of 1(2-Hydroxyethoxy)-methyl)-6-(phenylthio)thymine. Quant. Struct.-Act. Relat. 1996, 15, 389-394.
13. Kireev, D. B.; Chretien, J. R.; Raevsky, O. A. Molecular modeling and quantitative structure-activity studies of anti-HIV-1 2-heteroarylquinoline-4-amines. Eur. J. Pharmacol. 1995, 30, 395-402.
14. Gussio, R.; Pattabiraman, N.; Zaharevitz, D. W.; Kellogg, G. E.; Topol, I. A.; Rice, W. G.; Schaeffer, C. A.; Erickson, J. W.; Burt, S. K. All-atom models for the nonnucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: A 3D QSAR approach. J. Med. Chem. 1996, 39, 1645-1650.
15. Kireev, D. B.; Chretien, J. R.; Grierson, D. S.; Monneret, C. A 3D QSAR study of a series of HEPT analogues: The influence of conformational mobility on HIV-1 reverse transcriptase inhibition. J. Med. Chem. 1997, 40, 4257-4264.
16. Artico, M.; Silvestri, R.; Massa, S.; Loi, A. G.; Corrias, S.; Piras, G. 2-Sulfonyl-4-chloranilino moiety: A potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones. J. Med. Chem. 1996, 39, 522-530.
17. Fisher, M. A.; Yadav, P. N. S.; Yadav, J.; Kristol, D.; Arnold, E.; Modak, M. J. Identification of a pharmacophore for nucleoside analogue inhibitors directed at HIV-1 reverse transcriptase. J. Mol. Recog. 1994, 7, 211-214.
18. Buolamwini, J. K.; Raghavan, K.; Fesen, M. R.; Pommier, Y.; Kohn, K. W.; Weinstein, J. N. Application of the electrotopological state index to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors. Pharm. Res. (New York) 1996, 13, 1892-1895.
19. Zhao, H.; Neamati, N.; Sunder, S.; Hong, H.; Wang, S.; Milne, G. W. A.; Pommier, Y.; Burke, T. R. Hydrazide-containing inhibitors of HIV-1 integrase. J. Med. Chem. 1997, 40, 937-941.
20. Hong, H.; Neamati, N.; Wang, S.; Nicklaus, M. C.; Mazumder, A.; Zhao, H.; Burke, T. R.; Pommier, Y.; Milne, G. W. A. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J. Med. Chem. 1997, 40, 930-936.
21. Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S.; Nicklaus, M. C.; Milne, G. W. A.; Proksa, B.; Pommier, Y. Depsides and depsidones as inhibitors of HIV-1 integrase: Discovery of novel inhibitors through 3D database searching. J. Med. Chem. 1997, 40, 942-951.
22. Nicklaus, M. C.; Neamati, N.; Hong, H.; Mazumder, A.; Sunder, S.; Chen, J.; Milne, G. W.; Pommier, Y. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J. Med Chem. 1997, 40, 920-929.
23. Zhao, H.; Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S.; Milne, G. W. A.; Pommier, Y.; Burke, T. R. Coumarin-based inhibitors of HIV integrase. J. Med. Chem. 1997, 40, 242-249.
24. Fesen, M. R.; Pommier, Y.; Leteurtre, F.; Hiroguchi, S.; Yung, J.; Kohn, K. W. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem. Pharmacol. 1994, 48, 595-608.
25. Raghavan, K.; Buolamwini, J. K.; Fesen, M. R.; Pommier, Y.; Kohn, K. W.; Weinstein, J. N. Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: A comparative molecular field analysis (CoMFA) study. J. Med. Chem. 1995, 38, 890-897.
26. Joao, H. C.; De Vreese, K.; Pauwels, R.; De Clercq, E.; Henson, G. W.; Bridger, G. J. Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors. J. Med. Chem. 1995, 38, 3865-3873.
27. Debnath, A. K.; Jiang, S.; Strick, N.; Lin, K.; Haberfield, P.; Neurath, A. R. Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of gp120 envelope glycoprotein of the human immunodeficiency virus type 1. J. Med. Chem. 1994, 37, 1099-1108.
28. Weislow, O. S.; Kiser, R.; Fine, D. L.; Bader, J. P.; Shoemaker, R. H.; Boyd, M. R. New soluble formazan assay for HIV-1 cytopathic effects: application to high flux screening of synthetic and natural products for AIDS antiviral activity. J. Natl. Cancer Inst. 1989, 81, 577-586.
29. Klopman, G. MULTICASE 1. A hierarchical computer automated structure evaluation program. Quant. Struct.-Act. Relat. 1992, 11, 176-184.
30. Klopman, G. Artificial intelligence approach to structure-activity studies. Computer automated structure evaluation of biological activity of organic molecules. J. Am. Chem. Soc. 1984, 106, 7315-7321.
31. Larder, B. A.; Darby, G.; Richman, D. D. HIV with reduced sensitivity to ziaovudine (AZT) isolated during prolonged therapy. Science 1989, 243, 1731-1734.
32. St. Clair, M. H.; Martin, J. L.; Tudor-Williams, G.; Bach, M. C.; Vavro, C. L.; King, D. M.; Kellam, P.; Kemp, S. D.; Larder, B. A. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991, 253, 1557-1559.
33. Montaner, J. S. G.; Singer, J.; Schechter, M. T.; Raboud, J. M.; Tsoukas, C.; O'Shaughnessy, M.; Reudy, J.; Nagai, K.; Salomom, H.; Spira, B.; Wainberg, M. A. Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the multicentre Canadian AZD trial. AIDS 1993, 7, 189-196.
34. Richman, D. D.; Fischl, M. A.; Grieco, M. H.; Gottlieb, M. S.; Volberding, P. A.; Laskin, O. L.; Leedom, J. M.; Groopman, J. E.; Mildvan, D.; Hirsch, M. S.; Jackson, G. G.; Durack, D. T. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 1987, 377, 192-197.
35. Dainiak, N.; Worthington, M.; Riordon, M. A.; Kreczko, S.; Goldman, L. AZT inhibits proliferation in vitro of human haematopoietic progenitor cells. Br. J. Haematol. 1988, 69, 299-304.
36. Gallicchio, V. S.; Hughes, N. K.; Hulette, B. C. In vitro modulation of the toxicity associated with the use of zidovudine on normal murine, human, and murine retrovirus-infected hematopoietic progenitor stem cells with basic fibroblast growth and synergistic activity with interleukin-1. J. Leukoc. Biol. 1992, 51, 336-342.